Philip Morris International is a leading global organization in the tobacco industry, primarily known for manufacturing and distributing a variety of smokeable products, including cigarettes and heated tobacco devices. The company is committed to transforming its business by investing in reduced-risk products, promoting alternatives to traditional smoking, such as e-cigarettes and heated tobacco products that aim to deliver nicotine without the harmful effects associated with combustion. With a strong emphasis on innovation and sustainability, Philip Morris International is actively shifting its focus towards a smoke-free future, striving to create a healthier environment while still engaging its customer base. Read More
As of February 6, 2026, Philip Morris International (NYSE: PM) stands at a historic crossroads. Long regarded as the quintessential "Big Tobacco" play, the company has spent the last decade aggressively cannibalizing its own legacy combustible business to lead a global "smoke-free" revolution. Today, the results of this gamble are no longer speculative; they are [...]
Tobacco company Philip Morris International (NYSE:PM) met Wall Streets revenue expectations in Q4 CY2025, with sales up 6.8% year on year to $10.36 billion. Its non-GAAP profit of $1.70 per share was in line with analysts’ consensus estimates.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Philip Morris has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.2% to $172.32 per share while the index has gained 8.2%.
Join us as we dissect Philip Morris International's stock performance and explore whether it can thrive in a changing market landscape. Will it be a solid investment or a risky bet?
Philip Morris asked the FDA to allow reduced-risk claims for ZYN, citing advisory-panel-reviewed evidence that switching from cigarettes lowers several disease risks.
Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching completely to ZYN reduces their risk of many smoking-related diseases and we look forward to a decision by FDA.
